Rhythm Pharmaceuticals Q2 2024 GAAP EPS $(0.55) Beats $(0.71) Estimate, Sales $29.078M Beat $28.789M Estimate
Portfolio Pulse from Benzinga Newsdesk
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q2 2024 GAAP EPS of $(0.55), beating the estimate of $(0.71) and showing a significant improvement from $(0.82) last year. Sales were $29.078M, also beating the estimate of $28.789M and showing a 51.28% increase from $19.221M last year.
August 06, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals reported better-than-expected Q2 2024 results with EPS of $(0.55) beating the $(0.71) estimate and sales of $29.078M beating the $28.789M estimate. This shows significant improvement from last year.
The better-than-expected earnings and sales figures, along with significant year-over-year improvements, are likely to positively impact RYTM's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100